{"filings":[{"id":95513,"accession_number":"0001213900-26-050211","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"EMA rolling review for OST-HER2; ATGA aligns on 3-year OS endpoint; peak EU sales >$300M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA initiated rolling review of OST-HER2 CMA for preventing recurrence in resected pulmonary metastatic osteosarcoma.","EMA and Australia TGA agreed 3-year overall survival as approvable endpoint; seroconversion data supports CMA.","UK MHRA granted Advanced Therapy Medicinal Product (ATMP) designation to OST-HER2.","Company forecasts peak European osteosarcoma sales exceeding $300M, with over $50M expected in 2027.","Confirmatory Phase 3 trial initiation planned for Q3 2026 in Australia; FDA and MHRA meetings in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95512,"accession_number":"0001213900-26-039529","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"OS Therapies completes $5.25M registered direct offering, expects $4M non-dilutive funds from UK subsidiary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $5.25M; net proceeds ~$4.7M from offering of 2.5M shares (or pre-funded warrants) and 3.8M common warrants at $1.40/share.","Expects ~$2M VAT refunds from UK sub. in Q2 2026 and ~$2M R&D tax credits in H2 2026.","Combined funding expected to extend cash runway into 2027.","Targets OST-HER2 regulatory approvals (US FDA, UK MHRA, EU EMA) in H2 2026.","90-day lockup on further equity issuance; Ceros received 7% fee and warrants at $1.54."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108641,"accession_number":"0001213900-26-037476","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OS Therapies files prospectus supplement for resale of up to 10.5M shares by selling stockholders","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed prospectus supplement covering resale of up to 10,529,417 shares of common stock by selling stockholders.","Shares registered under existing S-3 shelf effective August 12, 2025.","No new shares issued; proceeds go to selling stockholders, not the company.","Legal opinion of Olshan Frome Wolosky LLP on share legality attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108640,"accession_number":"0001213900-26-024726","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"OS Therapies raises $2M via 10% OID convertible notes and warrants; $2.2M principal","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Gross proceeds $2M; notes carry 4% interest, mature March 4, 2027.","Warrants to purchase up to 1,666,667 shares at $1.40, 5-year term; 100% warrant coverage.","Conversion: mandatory upon qualified offering ≥$2.5M; voluntary at 90% of 10-day VWAP.","Proceeds to fund clinical trials, R&D, and working capital.","19.99% issuance cap without stockholder approval; resale registration to be filed within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108639,"accession_number":"0001213900-26-016408","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"OS Therapies extends warrant exercise inducement period to March 2, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company extended offering period for warrant inducement from Feb 10 to March 2, 2026.","Existing Warrants covering up to 5,382,148 shares may be exercised at $1.40 per share.","Exercise triggers issuance of new warrants for same number of shares at $1.40 per share.","Extension consented to by company’s warrant solicitation agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108638,"accession_number":"0001213900-26-003166","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"OS Therapies raises $7.53M via warrant exercise inducement from all 9 existing holders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $7.53M from exercise or pre-funding of 5,382,148 Existing Warrants at $1.40/share.","New Warrants issued for up to 5,382,148 shares at $1.40, exercisable immediately for 5 years.","Net proceeds to fund OST-HER2 BLA/MMA filings, commercial prep, and OS Animal Health spinoff.","BLA for OST-HER2 in metastatic osteosarcoma expected by end of January 2026 under Accelerated Approval.","Company expects cash runway into 2027; all 9 accredited investors offered agreed to participate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125095,"accession_number":"0001213900-25-100821","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"OSTX shareholders approve 200M share increase, Ayala issuance, and plan amendment at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Charter amendment to increase authorized shares from 50M to 150M approved with 12.6M For, 228K Against, 16.3K Abstain.","Ayala Issuance (shares/warrants equal to ≥20% of outstanding common stock) approved with 12.7M For, 112.5K Against.","Plan Amendment increasing shares available for issuance from 4M to 10M and raising individual performance-based cap approved (10.9M For, 1.9M Against).","All six director nominees elected: Paul Romness, John Ciccio, Avril McKean Dieser, Karim Galzahr, Olivier Jarry, Theodore Search."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125094,"accession_number":"0001213900-25-100019","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"OS Therapies adjourns 2025 annual meeting to Oct 21; posts investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Annual meeting adjourned on Oct 14; reconvenes virtually Oct 21 at 10:00 a.m. ET to allow more proxy solicitation time.","Issuance Proposal, Charter Amendment, and Auditor Ratification already received requisite votes per preliminary tabulation.","Company posted an investor presentation to ir.ostherapies.com on Oct 17; expect to use it in investor meetings.","Stockholders who haven't voted can vote until Oct 20 at 11:59 p.m. ET or at reconvened meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141794,"accession_number":"0001213900-25-093936","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OS Therapies files prospectus supplement for resale of up to 4.37M shares by selling stockholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement covers resale of up to 4,373,043 shares of common stock by selling stockholders.","Shares are being registered for resale under existing S-3 shelf (File No. 333-289443) declared effective August 12, 2025.","Company is not issuing new shares or raising capital from this resale registration.","Legal opinion on share legality from Olshan Frome Wolosky LLP filed as Exhibit 5.1.","Filing date: September 30, 2025; no change in business operations or financial guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141793,"accession_number":"0001213900-25-083396","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"OS Therapies completes warrant inducement, raises $3.8M; extends funding into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised ~$3.78M gross from exercise of 3,373,043 existing warrants at $1.12; issued new warrants at $3.00 exercise price.","New warrants have forced exercise provision if stock trades above $9.00 for 20 consecutive days; could provide over $20M.","Proceeds to accelerate OST-HER2 commercial launch for pulmonary metastatic osteosarcoma; company funded into 2027.","Removal of old $1.12 warrants reduces potential short selling activity, per CEO Paul Romness.","Offering completed with all remaining holders; substantially similar to prior inducement offers in June/July 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141792,"accession_number":"0001213900-25-080484","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"OS Therapies terminates $15M equity line; $4.2M raised, burn reduced","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated ELOC Purchase Agreement with Square Gate effective Aug 26, 2025; no outstanding borrowings or fees.","Recent warrant exercise exchange provided $4.2M gross proceeds to fund operations into mid-2026.","Projected monthly burn in H2 2025 significantly lower than H1 2025, completing Phase 2b and Phase 1b treatment phases.","Company focusing capital on advancing OST-HER2 toward approval and analyzing OST-504 prostate cancer data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141791,"accession_number":"0001213900-25-078152","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OS Therapies Q2 net loss $4.5M; FDA confirms RMAT, issues BLA number for OST-HER2, Phase 2b data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA confirmed OST-HER2 meets biological criteria for RMAT; issued BLA number for Accelerated Approval submission.","Phase 2b trial: 12-month EFS 35% vs 20% (p=0.0197), interim 2-year OS 66.6% vs 40% (p=0.0046).","Q2 2025 net loss $4.537M vs $1.557M YoY; EPS loss $0.19 on 25.1M shares vs $0.26 on 5.99M shares.","End of Phase 2 FDA meeting scheduled Aug 27, 2025; projected rolling BLA submission late Q3 2025.","$4.2M capital raise closed July 11; entered ATM offering up to $18M; commercial partner Eversana for possible 1H 2026 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141790,"accession_number":"0001213900-25-077431","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"OS Therapies amends bylaws to reduce stockholder meeting quorum to one-third of voting power","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Board approved amendment to Section 3.10 of Article III of the Bylaws on August 15, 2025.","Quorum for stockholder meetings changed to one-third of the voting power of outstanding shares entitled to vote, present in person or by proxy.","Amendment filed as Exhibit 3.1 via prospectus supplement on Form S-3ASR; no sale of securities by DoD is implied.","No proceeds to company; DoD may convert preferred stock or exercise warrant to receive up to 24,521,672 common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141789,"accession_number":"0001213900-25-063479","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-07-14T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"OS Therapies closes $4.2M warrant exercise inducement; extends cash runway to 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $4.2M gross from exercise of 3.8M existing warrants at $1.12/share; issued new warrants at $3.00/share.","Cash runway extended through 2026, beyond Sept 30, 2026 PRV sunset date for rare pediatric diseases.","Proceeds to support OST-HER2 regulatory efforts for osteosarcoma, advance OS Animal Health, close OST-504 prostate cancer study, and initiate AI-driven ADC modeling.","CEO Paul Romness highlighted End of Phase 2 meeting with FDA and Scientific Advice Meetings in UK/Europe.","New warrants exercisable for 5 years at $3.00/share; forced exercise if stock hits 300% of exercise price for 20 consecutive trading days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159698,"accession_number":"0001213900-25-058603","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"OS Therapies completes second closing of warrant inducement; raises ~$616K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing: holders exercised Existing Warrants for 550,004 shares at $1.12; issued New Warrants for 550,004 shares at $3.00, 5-year term.","Gross proceeds approximately $616,000 before transaction fees and expenses.","New Warrants include forced exercise provision if stock price reaches $9.00 or more for 20 consecutive trading days.","Resale registration statement for New Warrant Shares to be filed within 30 days of final closing, effective within 60 days.","Offering exempt from registration under Section 4(a)(2) of Securities Act and Rule 506(b) of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159697,"accession_number":"0001213900-25-056911","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"OS Therapies (OSTX) raises up to $8M via warrant exercise inducement; extends cash runway into H2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercise 1.57M old warrants ($1.12) for cash; receive new 5-year warrants at $3.00/sh.","Gross proceeds up to ~$8M; $1.76M already received, extending cash runway into H2 2026.","Proceeds to support regulatory/pre-commercial efforts for OST-HER2 in osteosarcoma.","Offering period June 20 to July 10, 2025; solicitation agent fee 5% of gross proceeds.","Company reiterates BLA submission to FDA in Q3 2025; potential PRV sale (most recent at $160M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159696,"accession_number":"0001213900-25-044875","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OS Therapies Q1 net op loss $3.876M; OST-HER2 BLA on track for Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net operating loss of $3.876M in Q1 2025 vs $1.490M in Q1 2024, due to trial closeout and regulatory prep costs.","Net loss per share of $0.18 on 21.249M shares vs $0.25 on 5.991M shares in prior year period.","Positive Phase 2b data for OST-HER2 in pediatric osteosarcoma; FDA Type D meeting feedback expected mid-June 2025.","Company on track to file BLA for OST-HER2 in Q3 2025 for accelerated approval in osteosarcoma.","Acquired three clinical-stage and eight preclinical listeria immunotherapy assets from Ayala Pharmaceuticals."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159695,"accession_number":"0001213900-25-032071","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.01","3.02","1.01","8.01","9.01"],"status":"ready","headline":"OS Therapies closes $8M asset acquisition from Ayala; eliminates $20M milestones, cuts royalty to 1.5%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $8M: $400k cash to Ayala, $100k to third party, $7.5M in stock (4,774,637 shares at VWAP).","Eliminated $3.5M Biologics License filing milestone and $16.5M in sales milestones for OST-HER2.","Royalty on OST-HER2, ADXS-503, ADXS-504 reduced from 10% to 1.5% of net sales (to Univ. of Pennsylvania).","Added three clinical-stage candidates (OST-AXAL for HPV, OST-503 for NSCLC, OST-PSA for prostate) and 8 preclinical constructs.","Issued 2,164,215 shares and a warrant for 2,166,381 shares (exercise $0.001, 3-yr term); additional 444,041 shares pending stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159694,"accession_number":"0001213900-25-030375","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Stockholders approve issuance of shares exceeding 20% of outstanding common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held April 9, 2025; proposal passed with 11,587,018 votes in favor (99.3% of votes cast).","Approval covers conversion of 1,775,750 Series A Preferred shares and exercise of warrants from private placement.","Issuance without regard to conversion/exercise limits can dilute existing holders by at least 20%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159693,"accession_number":"0001213900-25-027522","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OS Therapies adjourns Special Meeting due to lack of quorum; reconvenes April 9, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special Meeting on March 31, 2025 lacked quorum; no business was conducted.","Adjourned meeting reconvenes April 9, 2025 at 10:00 a.m. ET at Olshan Frome Wolosky LLP offices.","Record date remains February 12, 2025; proxies previously submitted will be voted unless revoked.","Company continues soliciting votes for proposals in the proxy statement filed February 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178079,"accession_number":"0001213900-25-026322","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OS Therapies reports FY2024 net operating loss of $10.9M; cash runway into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net operating loss $10.886M in 2024 vs $7.916M in 2023, driven by IPO costs.","Net loss per share $0.88 on 12.38M shares vs $1.46 on 5.43M shares in 2023.","Cash on hand expected to last into 2026 due to reduced burn rate starting Q2 2025.","Full Phase 2b OST-HER2 data to be presented June 2025; BLA submission targeted for year-end 2025.","Plans to divest anticipated Priority Review Voucher (PRV) from potential BLA approval."],"consensus_eps_estimate":-0.0816,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178078,"accession_number":"0001213900-25-007705","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["1.01","3.02","5.02","8.01","9.01"],"status":"ready","headline":"OS Therapies acquires Ayala's listeria IP for $8M, eliminates milestones, adds Phase 2 lung asset","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration $8M: $0.5M cash + $7.5M in OSTX shares; 180-day lock-up. Closes ~60 days.","Eliminates $3.5M BLA milestone and $16.5M in OST-HER2 sales milestones; royalty reduced from 10% to 1.5% under Penn License.","Adds Phase 2 ADXS-503 (NSCLC) and Phase 1 ADXS-504 (prostate) programs using Listeria monocytogenes platform.","Karim Galzahr appointed to board; managing partner at OKG Capital, over 30 yrs finance experience.","Company has $7.1M financing at $4/share; cash runway into 2026; no equity raises below $12 for 6 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178077,"accession_number":"0001213900-25-003886","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OS Therapies completes private placement raising ~$7.1M in gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate gross proceeds from first and second closings total approximately $7,103,000.","Second closing occurred on January 14, 2025, as previously disclosed.","Board determined placement is complete; no further closings expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178076,"accession_number":"0001213900-25-003460","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"OS Therapies completes second closing of $1.05M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing sold 263,250 units at $4.00 each, raising $1.053 million in gross proceeds.","Each unit consists of one share of Series A Convertible Preferred Stock and a warrant to purchase one common share.","Amendment to securities purchase agreement allows multiple closings up to $10 million, with final closing by Feb 15, 2025.","Investors in second closing include Tichenor Ventures, LLC; placement agent Brookline Capital Markets received $35,157 cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178075,"accession_number":"0001213900-25-000844","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"OS Therapies closes $6M private placement; funds operations into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $6.05M gross from sale of 1,512,500 units at $4.00/unit; each unit has Series A Convertible Preferred share and a warrant.","Conversion price of preferred is $4.00; warrant exercise price is $4.40 per share.","Cash runway expected into 2026; 98% of investment from pre-IPO or IPO investors.","Data update from OST-HER2 Phase 2b trial in osteosarcoma to be announced during JP Morgan Healthcare Conference week.","Company entered waiver with ELOC investor Square Gate Capital, including cash payments and issuance of additional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194748,"accession_number":"0001213900-24-113561","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"OS Therapies announces $6M private placement; OST-HER2 Phase 2b data in Jan 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6M from sale of 1.5M units at $4.00/unit; each unit = 1 share Series A convertible preferred + 1 warrant.","Initial conversion price $4.00, warrant exercise price $4.40; prices subject to reset with floor of $1.00 and ceiling $4.00.","Proceeds to fund working capital and support commercialization of OST-HER2 for recurrent metastatic osteosarcoma.","Phase 2b trial data for OST-HER2 expected during week of JP Morgan Healthcare Conference in January 2025.","95% of investment from pre-IPO and/or IPO investors; $6M provides cash runway into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194747,"accession_number":"0001213900-24-099094","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OS Therapies Q3 net loss $2.9M; Phase 2b osteosarcoma data due Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net operating loss $2.875M in Q3 2024 vs $2.006M in Q3 2023; EPS -$0.18 vs -$0.38.","Completed dosing all 41 patients in Phase 2b trial of OST-HER2 in resected recurrent osteosarcoma.","Topline Phase 2b data expected December 2024; seeking FDA Breakthrough Therapy designation.","Company completed IPO in Q3 2024; pre-revenue with future revenue expected from priority review voucher."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194746,"accession_number":"0001213900-24-093567","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"OS Therapies secures up to $15M equity line from Square Gate Capital over 24 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company can sell up to $15M of common stock to Square Gate at 95% of lowest VWAP during valuation period.","Investor prohibited from short sales or hedging; no warrants issued in the transaction.","Initial commitment shares equal to 3% of $15M issued as consideration to the investor.","Proceeds will fund clinical development programs and expand discovery and preclinical activities.","Registration statement covering resale of shares to be filed with SEC by November 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194745,"accession_number":"0001213900-24-091235","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"OS Therapies appoints two new independent directors; Chairman Goddard and Joacim Borg resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Colin Goddard (Chairman) and Joacim Borg resigned effective Oct 28, 2024; no disagreement with company operations.","Avril McKean Dieser appointed independent director; VP, Head Legal Patient Evidence at UCB; regulatory/commercialization expertise.","Olivier R. Jarry appointed independent director; co-founder/CEO of Libera Bio; 40+ years biopharma experience.","Company preparing for FDA discussion on pivotal trial of OST-HER2 for osteosarcoma; building infrastructure for potential commercial launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211045,"accession_number":"0001213900-24-071832","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"OS Therapies clarifies CUSIP change for common stock from 68764Y108 to 68764Y207","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New CUSIP 68764Y207 assigned effective August 5, 2024, replacing old CUSIP 68764Y108.","No share splits or similar actions occurred between August 1 and August 5, 2024.","All shares under old CUSIP are now identified under new CUSIP with same number of shares.","Market participants instructed to update records to use new CUSIP 68764Y207 for trades."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211044,"accession_number":"0001213900-24-069622","cik":1795091,"company_name":"OS Therapies Inc","ticker":"OSTX","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"OS Therapies reports Q2 2024 net operating loss of $1.557M; IPO raises $6.4M post-quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net operating loss $1.557M vs $2.505M in Q2 2023; EPS loss $0.26 on 5.991M shares.","IPO on July 31, 2024 raised $6.4M gross with no warrants; all preferred shares and debt converted to equity.","Post-IPO shares outstanding: 20.85M common shares, with 1.86M tradable; 18.99M under 6-month lockup.","Lead program OST-HER2 Phase 2b osteosarcoma trial final results expected Q4 2024; interim data from 39/41 patients.","Cash runway extended to mid-2025 based on IPO proceeds; company reports no debt post-IPO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":90189662.14285715,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}